Navigation Links
The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
Date:7/2/2012

WHITE PLAINS, N.Y. and PRINCETON, N.J., July 2, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society® (LLS) and Celator Pharmaceuticals, Inc. today announced a significant expansion of their partnership to support clinical development and potential registration of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML).

Under the new agreement, LLS will provide $5 million in funding, through its Therapy Acceleration Program (TAP), for the pivotal, phase 3, multicenter trial of CPX-351 versus conventional cytarabine plus daunorubicin in elderly patients with untreated secondary AML. Celator will provide the balance of funding for the study through its own financing activities.  Enrollment in the study is expected to begin later this year. Should the results confirm that CPX-351 improves overall survival in this patient population, the study will be used to support a New Drug Application (NDA) for CPX-351 in this indication with the U.S. Food and Drug Administration (FDA).

"This is the first time that LLS has provided follow-on funding to a development partner," said Louis DeGennaro, Ph.D., LLS's chief mission officer. "The very promising results of our initial collaboration, as well as Celator's demonstrated ability to pursue its research agenda effectively while working with the FDA to identify an efficient regulatory pathway, give us the confidence to provide an additional $5 million to make CPX-351 available to patients with AML as soon as possible."As part of a 2009 partnership, LLS provided $4.1 million to help fund Celator's Phase 2B multicenter, randomized, open-label trial of CPX-351 versus intensive salvage therapy in adult patients 18-65 years of age with AML in first relapse. The positive results of that trial plus the survival advantage observed in a simi
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
2. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
4. GHX CEO Bruce Johnson Recognized as Ernst & Young Rocky Mountain Region Entrepreneur of the Year 2012
5. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
6. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
7. Need for Reduced Healthcare Outlays Creates Strong Growth Potential for Medical Imaging Services, Says Frost & Sullivan
8. 2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia Pharmaceutical Markets Analyzed in New Research Reports
9. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
10. LHA Life Sciences & Medical Technologies Virtual Conference
11. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Md. , Oct. 17, 2014 ... for Medical Technology Policy: The Green ... the FDA, public and private payers, medical device ... clinicians, and other experts January 12, 2015 at ... and value of weight loss treatments.  Participants will ...
(Date:10/17/2014)...   InnFocus, Inc ., reported on results of 59 ... for up to 3 years with the InnFocus MicroShunt® ... Chicago . The Summit ... of the American Academy of Ophthalmology . The Company ... patients in 6 countries by early 2015. Logo ...
(Date:10/17/2014)... Mass. , Oct. 17, 2014   ndd ... function testing (PFT) employing precise ultrasound technology, announced that ... Choctaw Nation Healthcare Center , a 140,000 square ... Talihina, Oklahoma hospital serves a large ... southeastern Oklahoma and beyond. A ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
... N.J., Oct. 25, 2011 Omthera Pharmaceuticals, Inc., a ... J. Maines has joined the Company as Vice President ... to Chief Operating Officer, Drs. Ben Machielse, Mr. Maines ... at Omthera.   Mr. Maines brings to ...
... N.C., Oct. 25, 2011 GlaxoSmithKline, one of ... today announced the 10 winners of its GlaxoSmithKline ... Philadelphia-area healthcare nonprofit organizations will receive $400,000 in ... the underserved in their communities. Three ...
Cached Medicine Technology:Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 3
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... 20, 2014 This report provides ... Seizure, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ... special features on late-stage and discontinued projects. , ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... , SUNDAY, March 20 (HealthDay News) -- Firstborn ... of allergies, finds a new study. Japanese researchers surveyed ... and found that a child,s birth order did not seem ... firstborn children were more likely to have hay fever, pink ...
... San Diego, Calif., USA Today, during the 89th ... Dental Research, held in conjunction with the 40th Annual ... the 35th Annual Meeting of the Canadian Association for ... oral presentation on a research study titled "Biodegradable Tooth-binding ...
... Jenifer Goodwin HealthDay Reporter , FRIDAY, March ... an advisory panel to the U.S. Food and Drug ... and their removal "from the marketplace would benefit public ... Scientific Advisory Committee also said that menthols, minty flavor ...
... -- Girls in early adolescence who form friendships with boys ... a new research. The study included 400 female and ... interviewed annually over seven years about their friendship network and ... girls tend to limit their friendships to same-sex peers. But ...
... (HealthDay News) -- Orthodontic retainers, removable devices used to keep ... if they aren,t properly cleaned, finds a new study. ... of a group of study participants and found that about ... that can cause fungal infections, while 50 percent had ...
... will likely be the hardest hit as a result of ... previous catastrophic events. Approximately 23 percent of Japanese citizens currently ... the highest proportion of older people in any country ... whole is headed," said James Appleby, RPh, MPH, executive director ...
Cached Medicine News:Health News:Biodegradable tooth-binding micelles inhibit Streptococcus mutans biofilm growth 2Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 2Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 3Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 4Health News:Teen Girls Who Befriend Boys at Higher Risk for Substance Abuse 2Health News:Orthodontic Retainers Can Harbor Harmful Microbes 2Health News:Japanese tsunami underscores need for elder disaster preparedness 2
The ACP 215 is the automated closed system cell processor with integrated process control....
... throughout the world are facing difficult times ... of the blood supply in the face ... donor base. Clearly, these centers must find ... manage their existing donor pools, and to ...
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
Medicine Products: